Vivimed Labs Ltd (VIVIMEDLAB) — shareholding pattern, promoter holding, financials and share price
About Vivimed Labs Ltd (VIVIMEDLAB)
Vivimed Labs Ltd operates in the Pharmaceuticals industry, within the Healthcare sector. It trades on the NSE as VIVIMEDLAB and on the BSE under scrip code 532660. Its ISIN is INE526G01021.
Vivimed Labs Ltd, established in 1988, is primarily engaged in the Business of Active Pharmaceuticals Ingredients, CDMO Finished Dosage Formulation, Specialty Chemicals and Retail Branded Formulation manufacturing. [1] [2]
Listed peers in Pharmaceuticals: Kabra Drugs Ltd, Shelter Pharma Ltd, Vista Pharmaceuticals Ltd, Mangalam Drugs and Organics Ltd, ANG Lifesciences India Ltd, Rajnish Wellness Ltd.
Valuation & Returns
10 Jul 2026At ₹5.51 a share on 10 Jul 2026, Vivimed Labs Ltd (VIVIMEDLAB) was valued at a price-to-earnings ratio of -1.31x against an industry P/E of 36.41x. Solomo computes return on equity of 50.81% and return on capital employed of -8.75% from filed results. Earnings ratios use consolidated results for the twelve months Mar 2025 to Dec 2025.
- P/E
- -1.31x
- Industry P/E
- 36.41x
- EPS (TTM)
- ₹-4.21
- Book value / share
- ₹-4.24
- ROE
- 50.81%
- ROCE
- -8.75%
- ROA
- -3.79%
- Debt / equity
- -8.01x
- Dividend yield
- 0%
- EBITDA margin
- -11.73%
- 52-week range
- ₹5.15 – ₹27.99
Ratios are computed from filed results and the last recorded price. Not investment advice.
Financial Performance
Mar 2025In the year ended Mar 2025, Vivimed Labs Ltd (VIVIMEDLAB) reported revenue of ₹116 crore, net profit of ₹-32 crore and earnings per share of ₹-3.85. That compares with revenue of ₹149 crore and net profit of ₹-45 crore in Mar 2024. Figures are consolidated, as filed with the exchanges.
In the quarter ended Dec 2025, revenue was ₹16 crore and net profit ₹-17 crore (consolidated).
| Metric | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|
| Revenue (₹ cr) | 861 | 237 | 187 | 149 | 116 |
| Net profit (₹ cr) | -72 | -68 | -329 | -45 | -32 |
| EPS (₹) | -8.67 | -8.16 | -39.62 | -5.48 | -3.85 |
| Measure | 10Y | 5Y | 3Y | 1Y |
|---|---|---|---|---|
| Sales growth | -11.76% | -17.83% | -22.01% | -22.00% |
| Profit growth | - | - | - | 29.68% |
| Stock price CAGR | -24% | -27% | 0% | - |
Ownership Summary
Mar 2026As of Mar 2026, promoters hold 7.57% of Vivimed Labs Ltd (VIVIMEDLAB) (down 0.2 pp QoQ), foreign institutional investors (FII) hold 1.64% and domestic institutional investors (DII) hold 0%. Promoters have pledged 15.2% of their holding. Market capitalisation was ₹46 crore on 10 Jul 2026. Shareholding is filed quarterly with BSE and NSE; Solomo carries every filing back to Sep 2005.
Largest disclosed public shareholders in Mar 2026: KITARA PIIN 1102 9.37%, WILLIAM F HARVEY 1.65%, SAMEER MAHENDRA SAMPAT 1.64%, AMICORP CAPITAL (MAURITIUS) LIMITED 1.47%, ASHISH BHARATKUMAR SHAH 1.42%, MONARCH NETWORTH FINSERVE PRIVATE LIMITED 1.24%. Only stakes above the 1% disclosure threshold are named in filings.
| Quarter | Promoter | Pledged | FII | DII | Public |
|---|---|---|---|---|---|
| Mar 2026 | 7.57% | 15.2% | 1.64% | 0% | 92.43% |
| Dec 2025 | 7.77% | 14.8% | 1.64% | 0% | 92.23% |
| Sep 2025 | 7.77% | 14.8% | 1.64% | - | 92.23% |
| Jun 2025 | 7.77% | 14.8% | 1.64% | - | 92.23% |
| Mar 2025 | 20.94% | 37.1% | 1.64% | - | 79.06% |
| Dec 2024 | 20.94% | 37.1% | 1.64% | - | 79.06% |
| Sep 2024 | 20.94% | 37.1% | 1.64% | - | 79.06% |
| Jun 2024 | 20.94% | 37.1% | 1.64% | - | 79.06% |